Danaher outdoes low fourth-quarter revenue expectations, forecasts slow 2024
Danaher’s revenue for the last three months of 2023 dropped by 11.5% compared to the same time in 2022, yet this was a better outcome than expected, with revenue primarily generated from its molecular diagnostics subsidiary Cepheid, the company said Tuesday morning.
The conglomerate also noted that its core 2024 revenue is predicted to decline to “high-single digits” for the first quarter of 2024 and “low-single digits” for the whole year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.